Literature DB >> 8400286

Survival or death of individual proerythroblasts results from differing erythropoietin sensitivities: a mechanism for controlled rates of erythrocyte production.

L L Kelley1, M J Koury, M C Bondurant, S T Koury, S T Sawyer, A Wickrema.   

Abstract

Murine erythroid progenitors infected with the anemia-inducing strain of Friend virus (FVA cells) undergo apoptosis when deprived of erythropoietin (EPO). When cultured with EPO, they survive and complete terminal differentiation. Although cell volume is decreased and nuclear chromatin is condensed during both apoptosis and terminal differentiation, morphologic and biochemical distinctions between these two processes were observed. In apoptosis, homogeneous nuclear condensation with nuclear envelope loss occurred in cells that had not reached the stage of hemoglobin synthesis. In terminal erythroid differentiation, nuclear condensation with heterochromatin, euchromatin, and nuclear envelope preservation occurred simultaneously with hemoglobin synthesis. Cells with apoptotic morphology appeared asynchronously in EPO-deprived cultures, indicating that only a portion of the cells were undergoing apoptosis at any given time. The percentages of apoptotic cells and cleaved DNA increased with time in EPO-deprived cultures. Inhibition of DNA cleavage was directly proportional to EPO concentration over a wide physiologic range, demonstrating a heterogeneity in susceptibility to apoptosis based on variability in the EPO sensitivity of individual cells. A subpopulation of FVA cells with increased EPO sensitivity (decreased EPO requirement) was isolated from EPO-deprived cultures. This increased EPO sensitivity did not result from differences in EPO receptor number, affinity, or structure, suggesting that the differences are in the signal transduction pathway. These results indicate that control of red blood cell production involves both prevention of apoptosis by EPO and heterogeneity in the EPO requirement of individual progenitor cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8400286

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  37 in total

1.  Comparative analysis of different methodological approaches to the in vitro study of drug-induced apoptosis.

Authors:  V D Kravtsov; T O Daniel; M J Koury
Journal:  Am J Pathol       Date:  1999-10       Impact factor: 4.307

2.  Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575.

Authors:  Xiaoyu Yan; Philip J Lowe; Martin Fink; Alexander Berghout; Sigrid Balser; Wojciech Krzyzanski
Journal:  J Clin Pharmacol       Date:  2011-12-12       Impact factor: 3.126

3.  Adherence to macrophages in erythroblastic islands enhances erythroblast proliferation and increases erythrocyte production by a different mechanism than erythropoietin.

Authors:  Melissa M Rhodes; Prapaporn Kopsombut; Maurice C Bondurant; James O Price; Mark J Koury
Journal:  Blood       Date:  2007-11-09       Impact factor: 22.113

Review 4.  Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents.

Authors:  Sameer Doshi; Wojciech Krzyzanski; Susan Yue; Steven Elliott; Andrew Chow; Juan José Pérez-Ruixo
Journal:  Clin Pharmacokinet       Date:  2013-12       Impact factor: 6.447

5.  Polymeric IgA1 controls erythroblast proliferation and accelerates erythropoiesis recovery in anemia.

Authors:  Séverine Coulon; Michaël Dussiot; Damien Grapton; Thiago Trovati Maciel; Pamella Huey Mei Wang; Celine Callens; Meetu Kaushik Tiwari; Saurabh Agarwal; Aurelie Fricot; Julie Vandekerckhove; Houda Tamouza; Yael Zermati; Jean-Antoine Ribeil; Kamel Djedaini; Zeliha Oruc; Virginie Pascal; Geneviève Courtois; Bertrand Arnulf; Marie-Alexandra Alyanakian; Patrick Mayeux; Tomas Leanderson; Marc Benhamou; Michel Cogné; Renato C Monteiro; Olivier Hermine; Ivan C Moura
Journal:  Nat Med       Date:  2011-10-23       Impact factor: 53.440

6.  ID1 promotes expansion and survival of primary erythroid cells and is a target of JAK2V617F-STAT5 signaling.

Authors:  Andrew D Wood; Edwin Chen; Ian J Donaldson; Shilpa Hattangadi; Karly A Burke; Mark A Dawson; Diego Miranda-Saavedra; Harvey F Lodish; Anthony R Green; Berthold Göttgens
Journal:  Blood       Date:  2009-07-01       Impact factor: 22.113

7.  Differential gene expression during terminal erythroid differentiation.

Authors:  S Koury; S Yarlagadda; K Moskalik-Liermo; N Popli; N Kim; C Apolito; A Peterson; X Zhang; P Zu; J Tamburlin; D Bofinger
Journal:  Genomics       Date:  2007-08-31       Impact factor: 5.736

8.  Chromatin condensation in terminally differentiating mouse erythroblasts does not involve special architectural proteins but depends on histone deacetylation.

Authors:  Evgenya Y Popova; Sharon Wald Krauss; Sarah A Short; Gloria Lee; Jonathan Villalobos; Joan Etzell; Mark J Koury; Paul A Ney; Joel Anne Chasis; Sergei A Grigoryev
Journal:  Chromosome Res       Date:  2009-01-27       Impact factor: 5.239

9.  Apoptosis in erythroid progenitors deprived of erythropoietin occurs during the G1 and S phases of the cell cycle without growth arrest or stabilization of wild-type p53.

Authors:  L L Kelley; W F Green; G G Hicks; M C Bondurant; M J Koury; H E Ruley
Journal:  Mol Cell Biol       Date:  1994-06       Impact factor: 4.272

10.  Severe leukopenia and dysregulated erythropoiesis in SCID mice persistently infected with the parvovirus minute virus of mice.

Authors:  J C Segovia; J M Gallego; J A Bueren; J M Almendral
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.